Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment

Elvin Blanco; Takafumi Sangai; Angela Hsiao; Silvia Ferrati; Litao Bai; Xuewu Liu; Funda Meric-Bernstam; Mauro Ferrari

doi:10.1016/j.canlet.2012.07.027

Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment

Elvin Blanco, Takafumi Sangai, Angela Hsiao, Silvia Ferrati, Litao Bai, Xuewu Liu, Funda Meric-Bernstam, Mauro Ferrari

Investigational Cancer Therapeutics

Research output: Contribution to journal › Article › peer-review

60 Scopus citations

Abstract

Adequate drug delivery to tumors is hindered by barriers such as degradation and non-specific distribution. Nested incorporation of drug-containing nanoparticles within mesoporous silicon particles (MSVs), carriers rationally designed to enhance tumor transport, was hypothesized to result in pronounced and sustained antitumor efficacy. Paclitaxel (PTX)-containing poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) polymer micelles were favorably loaded within MSVs, after which drug release was significantly delayed. Antitumor efficacy analyses in mice bearing MDA-MB-468 breast tumors demonstrated significant tumor growth suppression following a single administration. Results highlight effective chemotherapeutic shuttling and site-specific controlled release afforded by MSVs, potentially translating towards improvements in patient outcomes and morbidity.

Original language	English (US)
Pages (from-to)	245-252
Number of pages	8
Journal	Cancer Letters
Volume	334
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2012.07.027
State	Published - Jul 1 2013

Keywords

Cancer nanomedicine
Mesoporous silicon particles
Multistage drug delivery
Paclitaxel
Polymer micelles

ASJC Scopus subject areas

Oncology
Cancer Research

MD Anderson CCSG core facilities

High Resolution Electron Microscopy Facility

Access to Document

10.1016/j.canlet.2012.07.027

Cite this

@article{5c6f9f99e93849169ba9322229532c6a,

title = "Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment",

abstract = "Adequate drug delivery to tumors is hindered by barriers such as degradation and non-specific distribution. Nested incorporation of drug-containing nanoparticles within mesoporous silicon particles (MSVs), carriers rationally designed to enhance tumor transport, was hypothesized to result in pronounced and sustained antitumor efficacy. Paclitaxel (PTX)-containing poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) polymer micelles were favorably loaded within MSVs, after which drug release was significantly delayed. Antitumor efficacy analyses in mice bearing MDA-MB-468 breast tumors demonstrated significant tumor growth suppression following a single administration. Results highlight effective chemotherapeutic shuttling and site-specific controlled release afforded by MSVs, potentially translating towards improvements in patient outcomes and morbidity.",

keywords = "Cancer nanomedicine, Mesoporous silicon particles, Multistage drug delivery, Paclitaxel, Polymer micelles",

author = "Elvin Blanco and Takafumi Sangai and Angela Hsiao and Silvia Ferrati and Litao Bai and Xuewu Liu and Funda Meric-Bernstam and Mauro Ferrari",

note = "Funding Information: We thank David L. Haviland (TMHRI) for assistance with flow cytometry, and James P. Barrish (Texas Children{\textquoteright}s Hospital) and Kenneth Dunner, Jr. (MD Anderson Cancer Center) for assistance with TEM. We are grateful to Raul A. Gonzalez (TMHRI) for histological preparation of tumor samples, and Matthew G. Landry for schematics. The authors gratefully acknowledge funding from a Department of Defense Breast Cancer Research Program (DOD BCRP) Innovator Award (W81XWH-09-1-0212) to M.F. E.B. gratefully acknowledges support from postdoctoral fellowships from DOD/BCRP (W81XWH-11-1-0103) and the Susan G. Komen Breast Cancer Foundation (KG101394).",

year = "2013",

month = jul,

day = "1",

doi = "10.1016/j.canlet.2012.07.027",

language = "English (US)",

volume = "334",

pages = "245--252",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment

AU - Blanco, Elvin

AU - Sangai, Takafumi

AU - Hsiao, Angela

AU - Ferrati, Silvia

AU - Bai, Litao

AU - Liu, Xuewu

AU - Meric-Bernstam, Funda

AU - Ferrari, Mauro

N1 - Funding Information: We thank David L. Haviland (TMHRI) for assistance with flow cytometry, and James P. Barrish (Texas Children’s Hospital) and Kenneth Dunner, Jr. (MD Anderson Cancer Center) for assistance with TEM. We are grateful to Raul A. Gonzalez (TMHRI) for histological preparation of tumor samples, and Matthew G. Landry for schematics. The authors gratefully acknowledge funding from a Department of Defense Breast Cancer Research Program (DOD BCRP) Innovator Award (W81XWH-09-1-0212) to M.F. E.B. gratefully acknowledges support from postdoctoral fellowships from DOD/BCRP (W81XWH-11-1-0103) and the Susan G. Komen Breast Cancer Foundation (KG101394).

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Adequate drug delivery to tumors is hindered by barriers such as degradation and non-specific distribution. Nested incorporation of drug-containing nanoparticles within mesoporous silicon particles (MSVs), carriers rationally designed to enhance tumor transport, was hypothesized to result in pronounced and sustained antitumor efficacy. Paclitaxel (PTX)-containing poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) polymer micelles were favorably loaded within MSVs, after which drug release was significantly delayed. Antitumor efficacy analyses in mice bearing MDA-MB-468 breast tumors demonstrated significant tumor growth suppression following a single administration. Results highlight effective chemotherapeutic shuttling and site-specific controlled release afforded by MSVs, potentially translating towards improvements in patient outcomes and morbidity.

AB - Adequate drug delivery to tumors is hindered by barriers such as degradation and non-specific distribution. Nested incorporation of drug-containing nanoparticles within mesoporous silicon particles (MSVs), carriers rationally designed to enhance tumor transport, was hypothesized to result in pronounced and sustained antitumor efficacy. Paclitaxel (PTX)-containing poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL) polymer micelles were favorably loaded within MSVs, after which drug release was significantly delayed. Antitumor efficacy analyses in mice bearing MDA-MB-468 breast tumors demonstrated significant tumor growth suppression following a single administration. Results highlight effective chemotherapeutic shuttling and site-specific controlled release afforded by MSVs, potentially translating towards improvements in patient outcomes and morbidity.

KW - Cancer nanomedicine

KW - Mesoporous silicon particles

KW - Multistage drug delivery

KW - Paclitaxel

KW - Polymer micelles

UR - http://www.scopus.com/inward/record.url?scp=84878251881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878251881&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.07.027

DO - 10.1016/j.canlet.2012.07.027

M3 - Article

C2 - 22858582

AN - SCOPUS:84878251881

SN - 0304-3835

VL - 334

SP - 245

EP - 252

JO - Cancer Letters

JF - Cancer Letters

IS - 2

ER -

Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this